Journal
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 28, Issue 9, Pages 1552-1555Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-19-0313
Keywords
-
Funding
- Health Research Board of Ireland [HRA_PHS/2013/397, HRA_PHS/2015/1142]
- European Commission (DG-SANCO)
- International Agency for Research on Cancer
- Danish Cancer Society (Denmark)
- Ligue Contre le Cancer
- Institut Gustave Roussy
- Mutuelle Generale de l'Education Nationale
- Institut National de la Sante et de la Recherche Medicale (France)
- Deutsche Krebshilfe
- Federal Ministry of Education and Research (Germany)
- Hellenic Health Foundation (Greece)
- Sicilian Government
- Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy
- National Research Council (Italy)
- Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds
- Dutch Prevention Funds
- Dutch ZON (Zorg Onderzoek Nederland)
- World Cancer Research Fund (WCRF)
- Statistics Netherlands (the Netherlands)
- Nordic Centre of Excellence programme on Food, Nutrition and Health
- Health Research Fund (FIS) [PI13/00061, 6236]
- Regional Government of Asturias (Asturias, Spain)
- ISCIII RETIC [RD06/0020]
- Swedish Cancer Society
- Swedish Scientific Council
- County Councils of Skane
- Vasterbotten (Sweden)
- Cancer Research UK [14136, C570/A16491]
- Medical Research Council [1000143, MR/M012190/1]
Ask authors/readers for more resources
Background: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort. Methods: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI). Results: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06). Conclusions: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk. Impact: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available